ITCH sirna

ITCH siRNA (Human)

Cat. Num. AAA8222511

• Gene Names: ITCH; AIF4; AIP4; ADMFD; NAPP1
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: ITCH; ITCH siRNA (Human); E3 ubiquitin-protein ligase Itchy homolog; Itch; Atrophin-1-interacting protein 4; AIP4; NFE2-associated polypeptide 1; NAPP1; ITCH sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: ITCH siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 903

• Applicable Applications for ITCH sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human ITCH gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for ITCH sirna

siRNA to inhibit ITCH expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 380420335
• NCBI GeneID: 83737
• NCBI Accession #: NP_001244066.1
• NCBI GenBank Nucleotide #: NM_001257137.1
• UniProt Accession #: Q96J02; O43584; Q5QP37; Q5TEL0; Q96F66; Q9BY75; Q9H451; Q9H4U5; A6NEW4; B4E234; E1P5P3; F5H217
• Molecular Weight: 86,498 Da
• NCBI Official Full Name: E3 ubiquitin-protein ligase Itchy homolog isoform 1
• NCBI Official Synonym Full Names: itchy E3 ubiquitin protein ligase
• NCBI Official Symbol: ITCH
• NCBI Official Synonym Symbols: AIF4; AIP4; ADMFD; NAPP1
• NCBI Protein Information: E3 ubiquitin-protein ligase Itchy homolog
• UniProt Protein Name: E3 ubiquitin-protein ligase Itchy homolog
• Protein Family: E3 ubiquitin-protein ligase
• UniProt Gene Name: ITCH
• UniProt Synonym Gene Names: Itch; AIP4; NAPP1
• UniProt Entry Name: ITCH_HUMAN

NCBI Description

This gene encodes a member of the Nedd4 family of HECT domain E3 ubiquitin ligases. HECT domain E3 ubiquitin ligases transfer ubiquitin from E2 ubiquitin-conjugating enzymes to protein substrates, thus targeting specific proteins for lysosomal degradation. The encoded protein plays a role in multiple cellular processes including erythroid and lymphoid cell differentiation and the regulation of immune responses. Mutations in this gene are a cause of syndromic multisystem autoimmune disease. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene. [provided by RefSeq, Mar 2012]

Uniprot Description

ITCH: an E3 ubiquitin-protein ligase which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates. It catalyzes 'Lys-29'-, 'Lys-48'- and 'Lys-63'-linked ubiquitin conjugation. It is involved in the control of inflammatory signaling pathways. Is an essential component of a ubiquitin-editing protein complex, comprising also TNFAIP3, TAX1BP1 and RNF11, that ensures the transient nature of inflammatory signaling pathways. Promotes the association of the complex after TNF stimulation. Once the complex is formed, TNFAIP3 deubiquitinates 'Lys-63' polyubiquitin chains on RIPK1 and catalyzes the formation of 'Lys-48'-polyubiquitin chains. This leads to RIPK1 proteasomal degradation and consequently termination of the TNF- or LPS-mediated activation of NFKB1. Ubiquitinates RIPK2 by 'Lys-63'-linked conjugation and influences NOD2-dependent signal transduction pathways. Regulates the transcriptional activity of several transcription factors, and probably plays an important role in the regulation of immune response. Ubiquitinates NFE2 by 'Lys-63' linkages and is implicated in the control of the development of hematopoietic lineages. Critical regulator of T-helper (TH2) cytokine development through its ability to induce JUNB ubiquitination and degradation. Ubiquitinates SNX9. Ubiquitinates CXCR4 and HGS/HRS and regulates sorting of CXCR4 to the degradative pathway. It is involved in the negative regulation of MAVS-dependent cellular antiviral responses. Ubiquitinates MAVS through 'Lys-48'-linked conjugation resulting in MAVS proteasomal degradation. Involved in the regulation of apoptosis and reactive oxygen species levels through the ubiquitination and proteasomal degradation of TXNIP. Mediates the antiapoptotic activity of epidermal growth factor through the ubiquitination and proteasomal degradation of p15 BID. Targets DTX1 for lysosomal degradation and controls NOTCH1 degradation, in the absence of ligand, through 'Lys-29'-linked polyubiquitination. Monomer Interacts (via its WW domains) with OCNL, NOTCH1 AND JUN. Interacts with JUNB; the interaction promotes ITCH-mediated ubiquitination and degradation of JUNB. Interacts with NDFIP1 and NDFIP2; this interaction activates the E3 ubiquitin-protein ligase and may induce its recruitment to exosomes. Interacts with ARHGEF7. Interacts with RNF11. Interacts (via the WW 1 domain) with NFE2 (via the PXY motif 1); the interaction promotes 'Lys-63'-linked ubiquitination of NFE2, retains it in the cytoplasm and prevents its transactivation activity. Interacts with FYN; the interaction phosphorylates ITCH on Tyr-420 decreasing binding of JUNB. Interacts (via WW domains) with CXCR4 (via C-terminus); the interaction depends on CXCR4 phosphorylation. Interacts (via WW domains) with PCBP2 within a complex containing ITCH, MAVS and PCBP2. Interacts (via WW domains) with TXNIP (via C-terminus). Interacts with ERBB4, DTX1, SPG20, SNX9 and SNX18. Interacts (via its WW domains) with ATN1. Interacts with Epstein-Barr virus LMP2A. Interacts (via WW domains) with SGK3. Widely expressed. 2 isoforms of the human protein are produced by alternative splicing.

Protein type: Ligase; EC 6.3.2.-; Ubiquitin ligase; Ubiquitin conjugating system; EC 6.3.2.19

Chromosomal Location of Human Ortholog: 20q11.22

Cellular Component: membrane; cytoplasm; plasma membrane; cell cortex; cytoplasmic vesicle; cytosol; nucleus

Molecular Function: ribonucleoprotein binding; protein binding; CXCR chemokine receptor binding; ubiquitin-protein ligase activity; ligase activity

Biological Process: ubiquitin-dependent protein catabolic process; negative regulation of JNK cascade; entry of virus into host cell; Notch signaling pathway; apoptosis; protein ubiquitination during ubiquitin-dependent protein catabolic process; protein ubiquitination; negative regulation of defense response to virus; inhibition of NF-kappaB transcription factor; positive regulation of protein catabolic process; negative regulation of alpha-beta T cell proliferation; innate immune response; regulation of cell growth; inflammatory response; negative regulation of interferon type I production; defense response to virus; positive regulation of T cell anergy; negative regulation of apoptosis

Disease: Autoimmune Disease, Multisystem, With Facial Dysmorphism